Basal Cell Carcinoma (BCC)
11
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
9%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
Flash Radiotherapy for Skin Cancer
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Intraoperative Margin Assessment During Mohs Surgery
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
Intralesional Cryosurgery for Basal Cell Carcinoma - a Feasibility Study